HARMONi-2 Interim Analysis: Ivonescimab Shows PFS Improvements Over Pembrolizumab in NSCLC
Ivonescimab showed significant improvements in progression-free survival compared with pembrolizumab in previously untreated advanced PD-L1–positive non-small cell lung cancer.